First Hawaiian Bank Makes New Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

First Hawaiian Bank bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 32,804 shares of the company's stock, valued at approximately $723,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEVA. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after acquiring an additional 2,067 shares during the period. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $50,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter worth about $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new position in shares of Teva Pharmaceutical Industries in the second quarter worth about $57,000. 54.05% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company's stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded down $0.52 during mid-day trading on Friday, hitting $20.97. 13,008,736 shares of the stock were exchanged, compared to its average volume of 8,123,877. The firm has a 50-day moving average of $18.89 and a two-hundred day moving average of $18.04. Teva Pharmaceutical Industries Limited has a 52-week low of $10.83 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a market cap of $23.76 billion, a PE ratio of -24.67, a price-to-earnings-growth ratio of 0.99 and a beta of 0.73.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TEVA shares. Barclays increased their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.88.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.